SCHEMBL5232285

SCHEMBL5232285

Cc1nn(C2CCCCC2)c(C(N)=O)c1NC(=O)c1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 2/20 0.43
CYP1A2 P05177 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
MET P08581 1/20 0.43
KDR P35968 1/20 0.43
MERTK Q12866 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
GRM4 Q14833 3/20 0.42
PDE7A Q13946 2/20 0.42
GRM5 P41594 1/20 0.42
MAPK1 P28482 1/20 0.41
NR3C1 P04150 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5235770 0.86 NR3C1 (0.43) NPC1RAB9APDE7ANR3C1
SCHEMBL5233570 0.80 KMT2A (0.47) SMN1; SMN2NPC1RAB9AEGFRPDE7A
SCHEMBL5237146 0.80 PDE7A (0.43) LMNAGAACYP1A2SMN1; SMN2PDE7A
SCHEMBL5233410 0.74 PDE7A (0.54) NPC1RAB9APDE7A
SCHEMBL5233614 0.73 EGFR (0.47) EGFRALDH1A1PDE7AMAPTKDM4E
SCHEMBL5233620 0.71 KMT2A (0.48) LMNASMN1; SMN2NPC1RAB9AEGFR
SCHEMBL5233613 0.71 KMT2A (0.48) LMNASMN1; SMN2NPC1RAB9AEGFR
SCHEMBL1814476 0.70 HPGD (0.47) HPGDALDH1A1PDE7ANR3C1KDM4E
SCHEMBL5238446 0.70 PDE7A (0.46) PKMLMNANPC1RAB9AALDH1A1
SCHEMBL5233784 0.67 KMT2A (0.48) LMNAHPGDSMN1; SMN2ALDH1A1PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PKM 649/4885LMNA 4228/4885GAA 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.